TrialClinical pharmacology and therapeutics2019

Exposure-Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection.

Mohamed-Eslam F Mohamed et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.